Business
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage
About this update from Nervgen Pharma Corp.
[{"type":"text","content":"VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Adams will continue in an advisory capacity following his retirement date to support the transition. “On behalf of the Board of Directors and our NervGen employees, I want to thank Bill for his financial and strategic leadership, as well as extend our sincere gratitude for his unwavering dedication and commitment to the Company,” said Adam Rogers, MD, President and Chief Executive Officer of NervGen. “Bill joined us at a critical moment in the lifecycle of the Company six years ago and has been a trusted colleague and advisor. His integrity, thoughtfulness, and commitment to our mission have been invaluable to me personally and to the entire organization. We're grateful for everything Bill has contributed to NervGen and wish him the best in a well-deserved retirement.” “I am honored to have served as Chief Financial Officer of NervGen and to have played a meaningful role in all that we’ve accomplished over the past several years,” Mr. Adams commented. “It gives me great joy to have helped guide the Company’s dramatic transformation from preclinical and first-in-human studies to a Nasdaq-listed company entering late-stage development for NVG-291, a therapeutic candidate with the potential to significantly impact the lives of so many around the world living with spinal cord injury.” “These past six years at NervGen has been unlike anything else I’ve had the opportunity to work on in my career, and I’m incredibly proud of the financial and operational foundation we’ve built. I believe the Company is well positioned, with a clear path ahead. I look forward to supporting NervGen during this transition and cheering on its continued success in the years to come,” Mr. Adams concluded. About NervGen PharmaNervGen Pharma Corp. (TSXV: NGEN) (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparat...